Baldo B, Cheong RY, Petersén ÅPLoS One 9(10) (2014)AbstractPsychiatric and metabolic features appear several years before motor disturbances in the neurodegenerative Huntington’s disease (HD), caused by an expanded CAG repeat in the huntingtin (HTT) gene. Although the mechanisms leading to these aspects are unknown, dysfunction in the hypothalamus, a brain region controlling emotion and metabolism

https://www.huntington-research.lu.se/effects-deletion-mutant-huntingtin-steroidogenic-factor-1-neurons-psychiatric-and-metabolic - 2025-07-01

Soylu-Kucharz R, Khoshnan A and Petersén Å. bioRxiv 2021.04.08.438894; First published April 9, 2021. https://doi.org/10.1101/2021.04.08.438894 Abstract Background Huntington’s disease (HD) is a neurodegenerative disorder caused by a CAG repeat expansion in the huntingtin (HTT) gene. Metabolic changes are associated with HD progression, and underlying mechanisms are not fully known. As the IKKβ/NF

https://www.huntington-research.lu.se/ikkb-signaling-mediates-metabolic-changes-hypothalamus-huntingtons-disease-mouse-model - 2025-07-01

Henningsen JB,  Soylu-Kucharz R, Björkqvist M and Petersén Å. Heliyon. 2021 Aug 14;7(8):e07808. doi: 10.1016/j.heliyon.2021.e07808. eCollection 2021 Aug. Abstract Huntington disease (HD) is a fatal neurodegenerative movement disorder caused by an expanded CAG repeat in the huntingtin gene (HTT). The mutant huntingtin protein is ubiquitously expressed, but only certain brain regions are affected. T

https://www.huntington-research.lu.se/effects-excitotoxicity-hypothalamus-transgenic-mouse-models-huntington-disease - 2025-07-01

Learn more from these short films where Åsa Petersén talks about cognitive symptoms and behavioural changes and psychiatric in Huntington's disease. Published by courtesy of Riksförbundet Huntingtons Sjukdom. All films are in Swedish. To view the Swedish subtitles, please click the button "CC" in the control bar (third from right) and choose "Svenska". Åsa Petersén about cognitive symptoms.   Åsa

https://www.huntington-research.lu.se/cognitive-symptoms-and-behavioural-changes - 2025-07-01

Gabery S, Kwa JE, Cheong RY, Baldo B, Ferrari Bardile C, Tan B, McLean C, Georgiou-Karistianis N, Poudel GR, Halliday G, Pouladi MA and Petersén Å.  Acta Neuropathologica. 142(5): 791-806 (2021) doi: 10.1007/s00401-021-02362-8. Abstract Huntington disease (HD) is a fatal neurodegenerative disorder caused by an expanded CAG repeat in the huntingtin (HTT) gene. The typical motor symptoms have been a

https://www.huntington-research.lu.se/early-white-matter-pathology-fornix-limbic-system-huntington-disease - 2025-07-01

Hyrskyluoto A, Bruelle C, Lundh SH, Do HT, Kivinen J, Rappou E, Reijonen S, Waltimo T, Petersén Å, Lindholm D and Korhonen L.Human Molecular Genetics 23: 5928-5939 (2014)AbstractHuntington's disease (HD) is an autosomal inherited neurological disease caused by a CAG repeat expansion in the first exon of huntingtin gene encoding for the huntingtin protein (Htt). In HD there is an accumulation of in

https://www.huntington-research.lu.se/ubiquitin-specific-protease-14-reduces-cellular-aggregates-and-protects-against-mutant-huntingtin - 2025-07-01

Dickson E, Soylu-Kucharz R , Petersén Å and Björkqvist M. Mol Metab. 2022 Mar;57:101439. doi: 10.1016/j.molmet.2022.101439. Epub 2022 Jan 7. Abstract Objective In Huntington's disease (HD), the disease-causing huntingtin (HTT) protein is ubiquitously expressed and causes both central and peripheral pathology. In clinical HD, a higher body mass index has been associated with slower disease progress

https://www.huntington-research.lu.se/hypothalamic-expression-huntingtin-causes-distinct-metabolic-changes-huntingtons-disease-mice - 2025-07-01

Soylu-Kucharz R, Khoshnan A and Petersén Å. iScience 2022 Jan 19;25(2):103771. doi: 10.1016/j.isci.2022.103771. eCollection 2022 Feb 18. Abstract Huntington's disease (HD) is a neurodegenerative disorder caused by a CAG repeat expansion in the huntingtin (HTT) gene. Metabolic changes are associated with HD progression, but underlying mechanisms are not fully known. As the IKKβ/NF-κB pathway is an

https://www.huntington-research.lu.se/ikkb-signaling-mediates-metabolic-changes-hypothalamus-huntingtons-disease-mouse-model-0 - 2025-07-01

Dickson E, Sai Dwijesha A, Andersson N, Lundh S, Björkqvist M, Petersén Å and Soylu-Kucharz R. Frontiers in Neuroscience. 2022 Nov 3;16:1027269. doi: 10.3389/fnins.2022.1027269. PMID: 36408416; PMCID: PMC9671106. Abstract Structural changes and neuropathology in the hypothalamus have been suggested to contribute to the non-motor manifestations of Huntington’s disease (HD), a neurodegenerative diso

https://www.huntington-research.lu.se/microarray-profiling-hypothalamic-gene-expression-changes-huntingtons-disease-mouse-models - 2025-07-01

Petersén Å1 and Kirik D2.1Translational Neuroendocrine Research Unit, Department of Experimental Medical Science, Lund University, Lund SE-221 84, Sweden.2Brain Repair and Imaging in Neural Systems (BRAINS) Unit, Department of Experimental Medical Science, Lund University, Lund SE-221 84, Sweden.Journal of Clinical Investigation 17:1-3 (2014)AbstractA common form of the hyperkinetic movement disor

https://www.huntington-research.lu.se/twisting-mice-move-dystonia-field-forward - 2025-07-01

Hellem MNN, Cheong RY, Tonetto S, Vinther-Jensen T, Hendel RK, Larsen IU, Nielsen TT, Hjermind LE, Vogel A, Budtz-Jørgensen E, Petersén Å and Nielsen JE. Parkinsonism and Related Disorders. 99: 23-29 (2022).  Abstract Objective: Huntington's disease (HD) is an inherited neurodegenerative disease with motor, cognitive and psychiatric symptoms. Non-motor symptoms like depression and altered social c

https://www.huntington-research.lu.se/decreased-csf-oxytocin-relates-measures-social-cognitive-impairment-huntingtons-disease-patients - 2025-07-01

Bergh S, Cheong R Y, Petersén Å and Gabery S. Front. Mol. Neurosci., 14 September 2022; Sec. Molecular Signalling and Pathways; doi.org/10.3389/fnmol.2022.984317   Abstract Neurodegenerative disorders (NDDs) such as Huntington’s disease (HD) and the spectrum of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are characterized by progressive loss of selectively vulnerable popu

https://www.huntington-research.lu.se/oxytocin-huntingtons-disease-and-spectrum-amyotrophic-lateral-sclerosis-frontotemporal-dementia - 2025-07-01

Furby H, Moore S, Nordstroem A-L, Houghton R, Lambrelli D, Graham S, Svenningsson P and Petersén Å. Journal of Neurology. 270(2): 864-876 (2023) doi:10.1007/s00415-022-11418-y. Abstract Background: Huntington's disease (HD) is a rare, neurodegenerative disease and its complex motor, cognitive and psychiatric symptoms exert a lifelong clinical burden on both patients and their families. Objective:

https://www.huntington-research.lu.se/comorbidities-and-clinical-outcomes-adult-and-juvenile-onset-huntingtons-disease-study-linked - 2025-07-01

https://www.lucc.lu.se/internal/landing-page-0 - 2025-07-01

- Facilitation: Stimulating cutting-edge cancer research LUCC strives to support excellent cutting-edge cancer research by creating optimal conditions to perform world-leading basic, translational and clinical studies. LUCC furthermore strives to include researchers from related research areas, to enhance interdisciplinary collaborations and viewpoints.Firstly, LUCC will be a driving force in the

https://www.lucc.lu.se/internal/research - 2025-07-01

LUCC is governed by the regulation "Dnr STYR 2024/2957" as decided by the Board of Faculty of Medicine at Lund University on 4 December, 2024. LUCC is managed by a board, internal reference group (network group leaders, scientific advisory board and supporting personnel. The term of office is usually 3 years (2 years for PhD student representatives and 1 year for Future Faculty representative) wit

https://www.lucc.lu.se/internal/organisation-governance - 2025-07-01

Summary statement: LUCC will act at the front-line to implement cutting-edge knowledge from basic and clinical research by addressing unmet clinical needs in close collaboration with the health care sector, industry and society-at-large.  VISIONLund University Cancer Centre is a leading actor in understanding malignant diseases, explaining their implications, and improving knowledge-based cancer p

https://www.lucc.lu.se/internal/strategic-plan - 2025-07-01

LUCC has 17 strategic translational networks based on cancer diagnosis, technology or processes. The aim of the networks is to bridge the basic and clinical science and the diverse disciplines. Networking activities include discussions about scientific challenges in the field, facilitation of new collaborations, and sharing technical and educational expertise. The key goal is to create opportuniti

https://www.lucc.lu.se/internal/research/strategic-networks - 2025-07-01

Breast cancer is the most common diagnosis among women worldwide, and the LUCC-Breast network is the largest cancer research area at Lund University. LUCC-Breast comprises over 20 groups and 150 members in Lund and Malmö. The scientific focus areas span from basic science to clinical studies, with major research projects within genomics, genetics, tumor biology, cell signaling, prognostic and pred

https://www.lucc.lu.se/internal/research/strategic-networks/lucc-breast-network - 2025-07-01

The UroCAN - LUCC center aims to develop healthcare and research with a focus on the three most common forms of urological cancer: prostate cancer, bladder cancer and kidney cancer. To goal of the network is to facilitate the collaboration between clinics, research, business and patient representatives to face current paradigm shifts with molecular diagnostics and new treatments. The aim of the ce

https://www.lucc.lu.se/internal/research/strategic-networks/urocan-lucc - 2025-07-01